The FDA has approved a label change to Bracco Diagnostics‘ MultiHance MRI contrast agent. The company’s product can now be used to visualize lesions with abnormal vascularity of the brain and spine in patients younger than two years old. Data collected in pediatric patients under the age of two showed that a dose of 0.05 […]
Bracco Diagnostics
Bracco Imaging explores using microbubbles to deliver personalized gene therapy
Bracco Imaging has launched a new effort at its Switzerland-based R&D center to evaluate gas-filled microbubbles, usually used for diagnostic imaging, as a delivery vehicle for personalized gene therapies to treat chronic dysfunctional diseases linked to lipid metabolism. The research project is part of a deal that Bracco signed with startup SonoGene, which is developing […]
Bracco Diagnostics wins another FDA nod for Lumason microspheres
Bracco Imaging U.S. subsidiary Bracco Diagnostics said today that it won FDA approval for its Lumason microsphere contrast agent to be used in ultrasonography of the urinary tract in pediatric patients with suspected or known vesicoureteral reflux. “The approval of Lumason for voiding ultrasonography answers an unmet medical need for an effective imaging study to […]
